Particular features of the clinical course of the papilloma viral infection depending on quantitative indices of human papilloma viruses of a high carcinogenic risk
- 作者: Rakhmatulina M.R.1, Bolshenko N.V.2, Kuevda D.A.3, Trofimova O.B.3
 - 
							隶属关系: 
							
- State Research Center of Dermatovenereology and Cosmetology, Ministry of healthcare of the Russian Federation
 - Russian Medical Academy of Postgraduate Studies, Ministry of Health Russian Federation
 - Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Right and Human Welfare
 
 - 期: 卷 90, 编号 3 (2014)
 - 页面: 95-104
 - 栏目: CLINICAL PRACTICE GUIDELINES
 - URL: https://bakhtiniada.ru/0042-4609/article/view/116611
 - DOI: https://doi.org/10.25208/0042-4609-2014-90-3-95-104
 - ID: 116611
 
如何引用文章
全文:
详细
关键词
作者简介
M. Rakhmatulina
State Research Center of Dermatovenereology and Cosmetology, Ministry of healthcare of the Russian Federation
							编辑信件的主要联系方式.
							Email: sanabol@mail.ru
				                					                																			                												                	俄罗斯联邦													
N. Bolshenko
Russian Medical Academy of Postgraduate Studies, Ministry of Health Russian Federation
														Email: sanabol@mail.ru
				                					                																			                												                	俄罗斯联邦													
D. Kuevda
Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Right and Human Welfare
														Email: sanabol@mail.ru
				                					                																			                												                	俄罗斯联邦													
O. Trofimova
Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Right and Human Welfare
														Email: sanabol@mail.ru
				                					                																			                												                	俄罗斯联邦													
参考
- Kuznetsova Y.N., Evstigneyeva N.P., Oboskalova T.A. Complex therapy of clinical manifestations of urogenital papilloma-virus infection. Modern probl of dermatovenereol, immunol and med cosmetol 2009; 3 (6): 27-31
 - Soloviyov A.M. Immunotherapy with isoprinosine as an adjuvant or independent method of treatment for patients with papilloma viral infection. Vestn dermatol i venerol 2011; 5: 146-151.
 - Rahmatulina M.R. Experience of the combined therapy of anogenital (veneral) warts. Vestn dermatol i venerol 2012; 4: 105-110.
 - Kaprin A.D. Zlokachestvennye novoobrazovaniya v Rossii v 2012 godu (zabolevaemost' i smertnost') / Pod redaktsiey A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoy. M: FGBU «MNIOI im. P.A. Gertsena» Minzdrava Rossii, 2014.
 - Mayrand M-H., Duarte-Franco E., Rodrigues I. et al. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. New England Journal of Medicine 2007; 357: 1579-1588.
 - Solomon D., Nayar R. The Bethesda System for reporting cervical cytology. Definition, criteria, and explanatory notes. Springer 2004; XXIII: 191.
 - Minkina G.N., Shabalova I.P. Klassifikatsiya patologicheskikh izmeneniy sheyki matki. Morfologicheskaya terminologiya. Profilaktika raka sheyki matki. Rukovodstvo dlya vrachey pod redaktsiey G.T. Sukhikh. M: 2012. 38-45.
 - Kitchener H.C., Peto J., Wheeler P. et al. ARTISTIC: a randomized train of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009 Nov; 13 (51): 1-150.
 - Ronco G., Biggeri A., Confortini M. et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer. Epidemiol Prev 2012 May-Aug; 36 (3-4 Suppl): e1-72.
 - Ronco G., Dillner J., Elfsröm K.M. et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four Europeen randomized controlled trials. The Lancet 2014 February; 383: 9916: 524-532.
 - Pileggi C., Flotta D., Bianco A., et al. Is HPV DNA testing specificity comparable to that of cytological testing in primary cervical cancer screening? Results of a meta - analysis of randomized controlled trials. HYPERLINK "http:// www.ncbi.nlm.nih.gov/pubmed/?term=Is+HPv+ DNA+testing+specificity+comparable+to+that+o f+cytological+testing+in+primary+cervical+can cer+screening%3F+Results+of+a+meta+%E2% 80%93+analysis+of+randomized+controlled+tri als" o "International journal of cancer. Journal international du cancer." Int J Cancer 2014 Jul 1; 135 (1): 166-77.
 - Kim J.J., Wright T.C., Goldie S.J. Cost - effectiveness of alternative triage studies for atypical squamous cells of undetermined significance. JAMA 2002; Vol. 287: 2382-2390.
 - Kim J.J., Wright T.C., Goldie S.J. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France and Italy. Journal of the National Cancer Institute 2005; 97 (12): 888-895.
 - Shipulina O.Yu. Algoritm diagnostiki virusa papillomy cheloveka. Spravochnik zaveduyushchego KDL 2010; 1: 3-11.
 - World Health Organization (WHO). Comprehensive cervical cancer control: a guide to essential practice. Geneva, 2010
 
补充文件
				
			
						
						
					
				

